News · 26 weeks27+40%
2026-03-012026-08-23
Mix1890d
- SEC Filings7(39%)
- Other6(33%)
- Analyst2(11%)
- Dividends1(6%)
- Earnings1(6%)
- Leadership1(6%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AGSCHEDULE 13D/A - Fresenius Medical Care AG (0001333141) (Subject)
- SECSEC Form 6-K filed by Fresenius Medical Care AG6-K - Fresenius Medical Care AG (0001333141) (Filer)
- SECSEC Form 6-K filed by Fresenius Medical Care AG6-K - Fresenius Medical Care AG (0001333141) (Filer)
- SECSEC Form 6-K filed by Fresenius Medical Care AG6-K - Fresenius Medical Care AG (0001333141) (Filer)
- SECSEC Form 6-K filed by Fresenius Medical Care AG6-K - Fresenius Medical Care AG (0001333141) (Filer)
- PRFresenius Medical Care appoints Cassie McLean as new Management Board Member for Care DeliveryBAD HOMBURG, Germany, Aug. 3, 2026 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care AG, the world's leading provider of products and services for individuals with renal disease, has appointed Cassie McLean (48) as a member of the Management Board, effective 1 August 2026. Ms. McLean will serve as Chief Executive Officer of the operating segment Care Delivery. She succeeds Craig Cordola (54) who previously served as Chief Executive Officer of Care Delivery. Ms. McLean joined Fresenius Medical Care in August 2025 as President, Fresenius Kidney Care. She will now assume direct accountability for the global clinic bu
- PRFresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agendaOrganic revenue growth1 of 5% with growth in all operating segmentsOperating income2 grew by 23%, resulting in further margin expansion to 11.7%Reported operating income grew by 10% and reported net income3 decreased by 3%Earnings per share2 (EPS) increased by 28%, supported by the share buyback program227 U.S. clinics converted to the 5008X CAREsystem with more than 600,000 treatments4Reaffirms FY 2026 outlookBAD HOMBURG, Germany, Aug. 3, 2026 /PRNewswire/ -- "Fresenius Medical Care delivered another quarter of highly profitable growth, driven by solid organic revenue growth and improved profitability," said Helen Giza, Chief Executive Officer of Fresenius Medical Care. "Care Delivery achie
- PRFresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patientsBEACON-US research initiative is evaluating the clinical outcomes and patient experiences of high-volume hemodiafiltration in routine U.S. clinical practice across diverse patient populationsFresenius Medical Care expands access to the therapy across the U.S. building on two decades of evidence and treatment from over 90 countries supporting improved survival and reduced hospitalizationBAD HOMBURG, Germany, July 29, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, today announced BEACON-US (Benefits, Effectiveness, And Convective Outcomes in Nephrology – United States), a comprehensive scientific re
- SECSEC Form 6-K filed by Fresenius Medical Care AG6-K - Fresenius Medical Care AG (0001333141) (Filer)
- ANALYSTFresenius Medical downgraded by BNP Paribas Exane with a new price targetBNP Paribas Exane downgraded Fresenius Medical from Neutral to Underperform and set a new price target of $19.90
- PRFresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapyCloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settingsAvailable within NxStage® System One™ with NxView™ 4.0, Fresenius Medical Care's FDA 510(k)-cleared software platform for kidney replacement therapy in the United StatesAggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variabilityBAD HOMBURG, Germany, July 20, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of TherapyWise™, a cloud-based ana
- ANALYSTBernstein initiated coverage on Fresenius MedicalBernstein initiated coverage of Fresenius Medical with a rating of Mkt Perform
- SECSEC Form 11-K filed by Fresenius Medical Care AG11-K - Fresenius Medical Care AG (0001333141) (Filer)
- PRFresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysisGlobal launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programsDesigned to simplify care processes for healthcare teams and their patients to support high-quality, personalized care for patients dialyzing at homeEnables managing peritoneal dialysis and home hemodialysis therapies across Fresenius Medical Care's global home dialysis portfolio in one digital platformBAD HOMBURG, Germany, June 3, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the global launch of kinexus, a unified digital platform designed to s
- SECSEC Form 6-K filed by Fresenius Medical Care AG6-K - Fresenius Medical Care AG (0001333141) (Filer)
- PRFresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 millionBAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1 billion. The first tranche, amounting up to EUR 600 million, was initiated today and is expected to be completed by December 15, 2026. The share buyback program is part of the Company's capital allocation framework, complementing dividends and reflecting FME's commitment to disciplined, value-fo
- SECSEC Form SD filed by Fresenius Medical Care AGSD - Fresenius Medical Care AG (0001333141) (Filer)
- PRFresenius Medical Care highlights new renal research and innovation at ERA Congress 2026Hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership in advancing evidence-based dialysis care and treatment personalizationNew research focuses on applying real-world evidence, patient-centered outcomes and artificial intelligence across dialysis modalities and continuity of kidney careA preview of kinexus, a unified digital platform intended to support home dialysis programs by connecting therapy management and care workflowsBAD HOMBURG, Germany, May 27, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, presents new research highlighting ongoing innovation at th
- SECSEC Form 6-K filed by Fresenius Medical Care AG6-K - Fresenius Medical Care AG (0001333141) (Filer)
- PRFresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 monthsTotal volume of the share buyback is around EUR 1 billion over 12 monthsShare buyback expected to begin in the near futureBAD HOMBURG, Germany, May 26, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, intends to execute a new share buyback program with a total volume of around EUR 1 billion. The program shall be executed in tranches over a period of 12 months from its start. The share buyback program is based on the authorization to purchase and use treasury shares granted by the Company
- PRFresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney careShareholders approve proposed dividend of EUR 1.49 per shareFME Reignite strategy launched in 2025 successfully drives the next phase of value creation5008X CAREsystem introduced in U.S. clinics; full U.S. commercial launch underway in 2026EUR 1 billion share buyback program successfully completed, and a new authorization granted to support the Company's capital allocation framework which includes share buyback programsBAD HOMBURG, Germany, May 21, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has completed a milestone year marked by significant improvements in profitability. Over the past three y
- PRFresenius Medical Care Reappoints Chief Financial Officer Martin FischerBAD HOMBURG, Germany, May 20, 2026 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care AG, the world's leading provider of products and services for individuals with renal disease, today has reappointed Chief Financial Officer (CFO) and Management Board Member Martin Fischer (49) for a period of five years until 2031. Michael Sen, Chairman of the Supervisory Board, commented, "Martin Fischer has demonstrated strong and consistent leadership and has further strengthened Fresenius Medical Care's governance, transparency, and financial discipline." Michael Sen added, "O
- SECSEC Form 6-K filed by Fresenius Medical Care AG6-K - Fresenius Medical Care AG (0001333141) (Filer)
- PRFresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speedOrganic revenue growth1 of 4% with growth in all operating segmentsOperating income2 grew 10%, resulting in further margin expansion to 10.1%FME25+ transformation program related one-time costs mainly drove reported operating income decline of 14% and reported net income3 decrease of 22%Earnings per share2 (EPS) increased by 16%, supported by the share buyback programFY 2026 outlook confirmedBAD HOMBURG, Germany, May 5, 2026 /PRNewswire/ -- "Fresenius Medical Care delivered continued operational and financial progress in the first quarter, with organic revenue growth, improved profitability and adjusted EPS growth. Operating income growth was in line with our planned phasing," said Helen Giz
- SECSEC Form 6-K filed by Fresenius Medical Care AG6-K - Fresenius Medical Care AG (0001333141) (Filer)
FMS FAQ
6 questionsWhat does Fresenius Medical Care AG do?
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients...Where does FMS stock trade?
Fresenius Medical Care AG (FMS) is listed on NYSE.What sector and industry is FMS in?
Fresenius Medical Care AG operates in the Health Care sector, Misc Health and Biotechnology Services industry.What are analysts saying about FMS?
Fresenius Medical Care AG has had 8 recent analyst actions on file. The most recent action was from BNP Paribas Exane: Underperform with a $1989.00 price target on 2026-07-28. Recent price targets range from $1989.00 to $2560.00.What companies are similar to FMS?
Notable peers in the same industry include DVA (DaVita Inc.), SHC (Sotera Health Company), PGNY (Progyny Inc.), AGL (agilon health inc.), VMD (Viemed Healthcare Inc.). Compare FMS side-by-side with any of them on Quantisnow.How can I track FMS on Quantisnow?
Quantisnow aggregates Fresenius Medical Care AG's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FMS to receive live email and push alerts on every new disclosure.